首页 > 最新文献

Future Science OA最新文献

英文 中文
DNA sequencing in oncology: a focus group study on a duty to recontact. 肿瘤学中的 DNA 测序:关于重新接触义务的焦点小组研究。
IF 2.4 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 Epub Date: 2024-11-22 DOI: 10.1080/20565623.2024.2432233
Noor A A Giesbertz, Lars S Assen, Wim H van Harten, Annelien L Bredenoord

Introduction: Particularly in genetics, former results can gain new meaning in the course of time. This raises questions about when professionals should recontact patients with new information. The aim of this focus group study is to clarify how different stakeholders in oncology think about the extent and limits of a duty to recontact.

Materials and methods: One focus group with oncology patients (n = 12) and two groups with healthcare professionals (total n = 13) were conducted. In general, there was support for recontacting patients. The scope and extent of this duty was, however, perceived differently. Differences and similarities on the following six contextual factors are discussed: information features, costs and efforts, personal preferences, who is contacted, clinic or research setting, and time.

Discussion: Oncology patients were clear in their wish to receive updates while the professionals were more hesitant to consider recontact as a standard of care. This is not surprising as recontacting patients with new information would mean a shift from a patient-initiated approach toward an information-initiated approach. This entails a different way of offering healthcare. Furthermore, the question is not only what professionals' responsibilities are, but how to design a system that complies with patients' wishes to receive updates.

导言:特别是在遗传学领域,以前的结果随着时间的推移会有新的意义。这就提出了专业人员何时应就新信息重新联系患者的问题。本焦点小组研究旨在阐明肿瘤学领域的不同利益相关者如何看待重新联系义务的范围和限度:开展了一个有肿瘤患者参加的焦点小组(12 人)和两个有医护人员参加的小组(共 13 人)。总体而言,重新联系患者得到了支持。但对这一职责的范围和程度却有不同看法。本文讨论了以下六个背景因素的异同:信息特征、成本和努力、个人偏好、联系对象、诊所或研究环境以及时间:肿瘤患者明确表示希望收到最新信息,而专业人员则对是否将重新联系作为一种护理标准犹豫不决。这并不奇怪,因为向患者重新提供新信息意味着从患者主动提供信息转变为信息主动提供信息。这意味着提供医疗服务的方式将发生变化。此外,问题不仅在于专业人员的责任是什么,还在于如何设计一个符合病人接收最新信息意愿的系统。
{"title":"DNA sequencing in oncology: a focus group study on a duty to recontact.","authors":"Noor A A Giesbertz, Lars S Assen, Wim H van Harten, Annelien L Bredenoord","doi":"10.1080/20565623.2024.2432233","DOIUrl":"10.1080/20565623.2024.2432233","url":null,"abstract":"<p><strong>Introduction: </strong>Particularly in genetics, former results can gain new meaning in the course of time. This raises questions about when professionals should recontact patients with new information. The aim of this focus group study is to clarify how different stakeholders in oncology think about the extent and limits of a duty to recontact.</p><p><strong>Materials and methods: </strong>One focus group with oncology patients (n = 12) and two groups with healthcare professionals (total n = 13) were conducted. In general, there was support for recontacting patients. The scope and extent of this duty was, however, perceived differently. Differences and similarities on the following six contextual factors are discussed: information features, costs and efforts, personal preferences, who is contacted, clinic or research setting, and time.</p><p><strong>Discussion: </strong>Oncology patients were clear in their wish to receive updates while the professionals were more hesitant to consider recontact as a standard of care. This is not surprising as recontacting patients with new information would mean a shift from a <i>patient-initiated</i> approach toward an <i>information-initiated</i> approach. This entails a different way of offering healthcare. Furthermore, the question is not only what professionals' responsibilities are, but how to design a system that complies with patients' wishes to receive updates.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2432233"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142692862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hyperhomocysteinemia prevalence among patients with venous thromboembolism. 静脉血栓栓塞症患者中的高同型半胱氨酸血症患病率。
IF 2.4 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 Epub Date: 2024-11-19 DOI: 10.1080/20565623.2024.2430417
R Ben Salah, M Boudaya, S Fendri, R Marrekchi, Z Bahloul, K Jamoussi

Aims: The objectives of this study were to determine the plasma homocysteine (Hcy) levels and the prevalence of Hyperhomocysteinemia (HHC) in a group of Tunisian patients with deep vein thrombosis (DVT) by comparing it with healthy controls.

Methods: it was an observational case-control study including patients hospitalized for the management of unprovoked DVT. For each subject, a routine biochemical assay was conducted, including plasma homocysteine measurement and determination of vitamin B12 and B9 levels, as these vitamins are essential for assessing hyperhomocysteinemia in DVT patients due to their role in regulating homocysteine.

Results: We observed an increased mean plasma Hcy level compared to controls and the prevalence of Hyperhomocysteinemia 61.7% against 4% in the control subjects. The risk of developing DVT with HHC is 3.54.

Conclusion: Our study found that homocysteine levels were higher in patients with DVT than in controls.

目的:本研究的目的是通过与健康对照组进行比较,确定一组突尼斯深静脉血栓(DVT)患者的血浆同型半胱氨酸(Hcy)水平和高同型半胱氨酸血症(HHC)患病率。对每位受试者都进行了常规生化检测,包括血浆同型半胱氨酸测定以及维生素 B12 和 B9 水平测定,因为这些维生素具有调节同型半胱氨酸的作用,对于评估深静脉血栓患者的高同型半胱氨酸血症至关重要:与对照组相比,我们观察到血浆 Hcy 平均水平升高,高同型半胱氨酸血症的发病率为 61.7%,而对照组为 4%。高同型半胱氨酸血症患者发生深静脉血栓的风险为 3.54:我们的研究发现,深静脉血栓患者的同型半胱氨酸水平高于对照组。
{"title":"Hyperhomocysteinemia prevalence among patients with venous thromboembolism.","authors":"R Ben Salah, M Boudaya, S Fendri, R Marrekchi, Z Bahloul, K Jamoussi","doi":"10.1080/20565623.2024.2430417","DOIUrl":"10.1080/20565623.2024.2430417","url":null,"abstract":"<p><strong>Aims: </strong>The objectives of this study were to determine the plasma homocysteine (Hcy) levels and the prevalence of Hyperhomocysteinemia <b>(</b>HHC) in a group of Tunisian patients with deep vein thrombosis (DVT) by comparing it with healthy controls.</p><p><strong>Methods: </strong>it was an observational case-control study including patients hospitalized for the management of unprovoked DVT. For each subject, a routine biochemical assay was conducted, including plasma homocysteine measurement and determination of vitamin B12 and B9 levels, as these vitamins are essential for assessing hyperhomocysteinemia in DVT patients due to their role in regulating homocysteine.</p><p><strong>Results: </strong>We observed an increased mean plasma Hcy level compared to controls and the prevalence of Hyperhomocysteinemia 61.7% against 4% in the control subjects. The risk of developing DVT with HHC is 3.54.</p><p><strong>Conclusion: </strong>Our study found that homocysteine levels were higher in patients with DVT than in controls.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2430417"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transforming Healthcare: The power and potential of digital medicine. 变革医疗保健:数字医疗的力量和潜力。
IF 2.4 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 Epub Date: 2024-11-22 DOI: 10.1080/20565623.2024.2430357
M Thirumal, S Monika
{"title":"Transforming Healthcare: The power and potential of digital medicine.","authors":"M Thirumal, S Monika","doi":"10.1080/20565623.2024.2430357","DOIUrl":"10.1080/20565623.2024.2430357","url":null,"abstract":"","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2430357"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Red cell distribution width-to-platelet ratio (RPR) as a predictor of prolonged stay at hospital for COVID-19 inpatients. 红细胞分布宽度与血小板比值(RPR)作为 COVID-19 住院患者住院时间延长的预测指标。
IF 2.4 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 Epub Date: 2024-11-22 DOI: 10.1080/20565623.2024.2432180
Martha Fors, Santiago J Ballaz
<p><strong>Aims/background: </strong>We looked at novel hematological composites like the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, red cell distribution width-to-lymphocyte ratio, red cell distribution width-to-platelet ratio, leukocyte-to-C reactive protein ratio, and lymphocyte-to-C reactive protein ratio as explanatory variables for COVID-19 patients´ hospital length of stay (LoS).</p><p><strong>Methods: </strong>The association of hematological indices with LoS was analyzed on 2930 COVID-19 patients using the univariate and multivariable Cox proportional hazards regression models with enter method. The Kaplan-Meier survival estimates were applied to LoS.</p><p><strong>Results: </strong>The survivors´ mean LoS was 7.8 ± 24.0 days, but the deaths´ mean LoS was 38.6 ± 41.9 days (W = 31338, p < 0.01). Every hematological scores representative of the inflammatory status was significantly correlated in the univariate analysis with a prolonged LoS (p < 0.001). In the multivariate analysis, it was discovered that just the monocyte-to-lymphocyte and lymphocyte-to-C reactive protein ratios had not achieved statistical significance. However, most systemic inflammation measures showed hazards ratios close to one. One exemption was the red cell distribution width-to-platelet ratio (RPR) index, which can increase the probability of a longer hospital stay by up to ten times (HR(IC95%) = 0.092(0.03-0.29); p < 0.001).</p><p><strong>Conclusion: </strong>The most effective biomarker to identify COVID-19 patients at high risk for extended hospital stay was RPR.</p><p><strong>Highlights: </strong><b>Introduction</b>Determining hospital Length of Stay (LoS) is vital for resource management, especially for future COVID-19 outbreaks.Previous studies have primarily focused on sociodemographic and clinical attributes, along with resource availability, but have not accounted for other factors like routine laboratory tests, which can significantly impact LoS predictions.This study examines novel hematology scores as predictors of LoS, emphasizing their importance in resource-limited settings like Ecuador.<b>Methods</b>This retrospective cohort study analyzed 2,930 COVID-19 patients admitted to Hospital IESS Quito Sur in Ecuador focusing on confirmed cases with complete blood count (CBC) values to assess LoS.The study explored various hematological ratios, such as the neutrophil-to-lymphocyte ratio (NLR) and red cell distribution width-to-lymphocyte ratio (RLR), as potential predictors of LoS and in-hospital outcomes for COVID-19 patients, using a combination of univariate and multivariable Cox proportional hazards regression models.Kaplan-Meier survival estimates and log-rank tests were used to analyze survival and discharge probabilities over time, highlighting sex-dependent effects and the significant association between selected hematological indices and patient outcomes.<b>Results</b>The mean LoS for survivors was s
目的/背景:我们将中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值、单核细胞与淋巴细胞比值、红细胞分布宽度与淋巴细胞比值、红细胞分布宽度与血小板比值、白细胞与C反应蛋白比值、淋巴细胞与C反应蛋白比值等新型血液学复合指标作为COVID-19患者住院时间(LoS)的解释变量:采用单变量和多变量 Cox 比例危险回归模型及 enter 方法分析了 2930 例 COVID-19 患者的血液指标与住院时间的关系。对LoS进行了Kaplan-Meier生存估计:结果:存活者的平均存活期为(7.8 ± 24.0)天,而死亡者的平均存活期为(38.6 ± 41.9)天(W = 31338,p 结论:存活者的平均存活期为(7.8 ± 24.0)天,而死亡者的平均存活期为(38.6 ± 41.9)天:RPR是识别COVID-19患者延长住院时间高风险的最有效生物标志物:导言:确定住院时间(LoS)对资源管理至关重要,尤其是在未来爆发 COVID-19 时。以前的研究主要关注社会人口学和临床属性以及资源可用性,但没有考虑常规实验室检查等其他因素,而这些因素会对 LoS 预测产生重大影响。这项回顾性队列研究分析了厄瓜多尔 IESS Quito Sur 医院收治的 2,930 名 COVID-19 患者,重点关注具有全血细胞计数 (CBC) 值的确诊病例,以评估 LoS。研究采用单变量和多变量考克斯比例危险回归模型,探讨了各种血液学比率,如中性粒细胞与淋巴细胞比率(NLR)和红细胞分布宽度与淋巴细胞比率(RLR),将其作为COVID-19患者LoS和院内预后的潜在预测因子。卡普兰-梅耶生存估计值和对数秩检验用于分析随时间变化的生存率和出院概率,突出了性别依赖效应以及选定的血液学指标与患者预后之间的显著关联。结果 与死亡患者相比,幸存者的平均存活时间明显较短(p < 0.001),这表明住院时间越长,死亡风险越高。女性的平均存活时间较短(死亡风险较低(p < 0.001),这表明住院模式与性别不对称。虽然大多数血液学指标与住院时间的临床相关性很小,但红细胞分布宽度与血小板比值(RPR)却很突出,它使住院时间延长的可能性增加了十倍,成为预测住院时间延长的关键因素。讨论与女性相比,男性的住院时间更长,死亡率更高,这可能是由于炎症反应不同造成的,尽管NLR、PLR和Leu-CPR等高炎症指标对临床影响很小。RPR升高与氧化应激和凝血问题有关,这表明早期识别有助于减少住院时间和并发症。结论研究普遍认为COVID-19引起的临床并发症是导致住院时间延长的主要因素,这强调了早期识别和管理这些问题的重要性。
{"title":"Red cell distribution width-to-platelet ratio (RPR) as a predictor of prolonged stay at hospital for COVID-19 inpatients.","authors":"Martha Fors, Santiago J Ballaz","doi":"10.1080/20565623.2024.2432180","DOIUrl":"10.1080/20565623.2024.2432180","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Aims/background: &lt;/strong&gt;We looked at novel hematological composites like the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, red cell distribution width-to-lymphocyte ratio, red cell distribution width-to-platelet ratio, leukocyte-to-C reactive protein ratio, and lymphocyte-to-C reactive protein ratio as explanatory variables for COVID-19 patients´ hospital length of stay (LoS).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;The association of hematological indices with LoS was analyzed on 2930 COVID-19 patients using the univariate and multivariable Cox proportional hazards regression models with enter method. The Kaplan-Meier survival estimates were applied to LoS.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The survivors´ mean LoS was 7.8 ± 24.0 days, but the deaths´ mean LoS was 38.6 ± 41.9 days (W = 31338, p &lt; 0.01). Every hematological scores representative of the inflammatory status was significantly correlated in the univariate analysis with a prolonged LoS (p &lt; 0.001). In the multivariate analysis, it was discovered that just the monocyte-to-lymphocyte and lymphocyte-to-C reactive protein ratios had not achieved statistical significance. However, most systemic inflammation measures showed hazards ratios close to one. One exemption was the red cell distribution width-to-platelet ratio (RPR) index, which can increase the probability of a longer hospital stay by up to ten times (HR(IC95%) = 0.092(0.03-0.29); p &lt; 0.001).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;The most effective biomarker to identify COVID-19 patients at high risk for extended hospital stay was RPR.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Highlights: &lt;/strong&gt;&lt;b&gt;Introduction&lt;/b&gt;Determining hospital Length of Stay (LoS) is vital for resource management, especially for future COVID-19 outbreaks.Previous studies have primarily focused on sociodemographic and clinical attributes, along with resource availability, but have not accounted for other factors like routine laboratory tests, which can significantly impact LoS predictions.This study examines novel hematology scores as predictors of LoS, emphasizing their importance in resource-limited settings like Ecuador.&lt;b&gt;Methods&lt;/b&gt;This retrospective cohort study analyzed 2,930 COVID-19 patients admitted to Hospital IESS Quito Sur in Ecuador focusing on confirmed cases with complete blood count (CBC) values to assess LoS.The study explored various hematological ratios, such as the neutrophil-to-lymphocyte ratio (NLR) and red cell distribution width-to-lymphocyte ratio (RLR), as potential predictors of LoS and in-hospital outcomes for COVID-19 patients, using a combination of univariate and multivariable Cox proportional hazards regression models.Kaplan-Meier survival estimates and log-rank tests were used to analyze survival and discharge probabilities over time, highlighting sex-dependent effects and the significant association between selected hematological indices and patient outcomes.&lt;b&gt;Results&lt;/b&gt;The mean LoS for survivors was s","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2432180"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single nucleotide polymorphisms: impact on susceptibility to chemotherapy in patients with colorectal cancer. 单核苷酸多态性:对结直肠癌患者化疗敏感性的影响。
IF 2.4 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 Epub Date: 2024-11-22 DOI: 10.1080/20565623.2024.2428077
M Angeles Vaz-Salgado, Victor Albarran, Javier Pozas, Reyes Ferreiro, Vanessa Pachón, Federico Longo, Mercedes Rodriguez, Emma Barreto, Julie Earl

Background: Single-nucleotide polymorphisms (SNPs) in enzyme-coding genes play a role in susceptibility to anti-cancer therapy.

Materials & methods: A prospective study was performed of the relationship between enzyme activity and treatment response, drug toxicity and hypersensitivity reactions in 51 patients with colorectal cancer treated with fluoropyrimidine-based chemotherapy. SNP analysis was performed in 22 enzyme-coding genes with a previously described role in treatment efficacy.

Results: SLC6 and MTHR enzyme activity was related with rates of progressive disease, GSTP1 activity with anti-EGFR antibodies-related skin toxicity, CYP3A5 and MTHR with chemotherapy dose reduction, CYP2B6, IL10, MTHR and TYMS activity with the risk of drug hypersensitivity reactions.

Conclusion: Pharmacogenetics is a valuable predictive marker in oncology, related to chemotherapy treatment response, toxicity and hypersensitivity.

背景:酶编码基因中的单核苷酸多态性(SNPs)在抗癌治疗的易感性中发挥作用:对51名接受氟嘧啶类化疗的结直肠癌患者的酶活性与治疗反应、药物毒性和超敏反应之间的关系进行了前瞻性研究。研究对 22 个酶编码基因中的 SNP 进行了分析,这些基因以前曾被描述过在疗效中的作用:结果:SLC6和MTHR酶活性与疾病进展率有关,GSTP1活性与抗EGFR抗体相关的皮肤毒性有关,CYP3A5和MTHR与化疗剂量减少有关,CYP2B6、IL10、MTHR和TYMS活性与药物超敏反应风险有关:药物遗传学是肿瘤学中与化疗反应、毒性和超敏反应相关的重要预测指标。
{"title":"Single nucleotide polymorphisms: impact on susceptibility to chemotherapy in patients with colorectal cancer.","authors":"M Angeles Vaz-Salgado, Victor Albarran, Javier Pozas, Reyes Ferreiro, Vanessa Pachón, Federico Longo, Mercedes Rodriguez, Emma Barreto, Julie Earl","doi":"10.1080/20565623.2024.2428077","DOIUrl":"10.1080/20565623.2024.2428077","url":null,"abstract":"<p><strong>Background: </strong>Single-nucleotide polymorphisms (SNPs) in enzyme-coding genes play a role in susceptibility to anti-cancer therapy.</p><p><strong>Materials & methods: </strong>A prospective study was performed of the relationship between enzyme activity and treatment response, drug toxicity and hypersensitivity reactions in 51 patients with colorectal cancer treated with fluoropyrimidine-based chemotherapy. SNP analysis was performed in 22 enzyme-coding genes with a previously described role in treatment efficacy.</p><p><strong>Results: </strong>SLC6 and MTHR enzyme activity was related with rates of progressive disease, GSTP1 activity with anti-EGFR antibodies-related skin toxicity, CYP3A5 and MTHR with chemotherapy dose reduction, CYP2B6, IL10, MTHR and TYMS activity with the risk of drug hypersensitivity reactions.</p><p><strong>Conclusion: </strong>Pharmacogenetics is a valuable predictive marker in oncology, related to chemotherapy treatment response, toxicity and hypersensitivity.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2428077"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the potential of Fargesin from Chrysanthemum indicum for chronic migraine: in-silico and pharmacokinetic study. 探索从菊花中提取的 Fargesin 治疗慢性偏头痛的潜力:硅内和药代动力学研究。
IF 2.4 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 Epub Date: 2024-11-19 DOI: 10.1080/20565623.2024.2428119
Rapuru Rushendran, Vellapandian Chitra

Introduction: Chronic migraine is recognized by the WHO as one of the most debilitating chronic conditions. It is primarily caused by central sensitization of the trigeminal nucleus caudalis. Key biomarkers associated with migraine include NFkB, IL-1β, CGRP, and iNOS. While CGRP antagonists have proven effective in treating migraines, Chrysanthemum indicum L., a traditional herbal remedy, has not been established as a treatment.

Methods: To address this, we investigated whether Fargesin, a lignan found in CI, could potentially reduce migraines by targeting these biomarkers. We conducted pharmacokinetic, toxicological, and in-silico studies. Molecular docking studies revealed a strong interaction between Fargesin and CGRP/iNOS.

Results: The pharmacokinetic analysis indicated robust intestinal absorption and effective penetration of the blood-brain barrier. In-silico toxicity assessments showed favorable results. Promising interactions with drug targets were observed in bioactivity tests.

Conclusion: Fargesin from Chrysanthemum indicum may hold potential as a therapeutic agent for migraines.

导言:慢性偏头痛被世界卫生组织认定为最令人衰弱的慢性疾病之一。它主要是由三叉神经尾核的中枢敏化引起的。与偏头痛相关的主要生物标志物包括 NFkB、IL-1β、CGRP 和 iNOS。虽然 CGRP 拮抗剂已被证明能有效治疗偏头痛,但传统草药菊花(Chrysanthemum indicum L.)尚未被确定为一种治疗方法:为了解决这个问题,我们研究了菊花中的木质素 Fargesin 是否有可能通过靶向这些生物标志物来减少偏头痛。我们进行了药代动力学、毒理学和分子内研究。分子对接研究显示 Fargesin 与 CGRP/iNOS 之间有很强的相互作用:药代动力学分析表明,Fargesin 有很好的肠道吸收能力,并能有效穿透血脑屏障。药物动力学分析表明该药物具有良好的肠道吸收性和有效的血脑屏障渗透性。在生物活性测试中观察到了与药物靶点的良好相互作用:结论:从菊花中提取的 Fargesin 可能具有治疗偏头痛的潜力。
{"title":"Exploring the potential of Fargesin from <i>Chrysanthemum indicum</i> for chronic migraine: <i>in-silico</i> and pharmacokinetic study.","authors":"Rapuru Rushendran, Vellapandian Chitra","doi":"10.1080/20565623.2024.2428119","DOIUrl":"10.1080/20565623.2024.2428119","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic migraine is recognized by the WHO as one of the most debilitating chronic conditions. It is primarily caused by central sensitization of the trigeminal nucleus caudalis. Key biomarkers associated with migraine include NFkB, IL-1β, CGRP, and iNOS. While CGRP antagonists have proven effective in treating migraines, Chrysanthemum indicum L., a traditional herbal remedy, has not been established as a treatment.</p><p><strong>Methods: </strong>To address this, we investigated whether Fargesin, a lignan found in CI, could potentially reduce migraines by targeting these biomarkers. We conducted pharmacokinetic, toxicological, and in-silico studies. Molecular docking studies revealed a strong interaction between Fargesin and CGRP/iNOS.</p><p><strong>Results: </strong>The pharmacokinetic analysis indicated robust intestinal absorption and effective penetration of the blood-brain barrier. In-silico toxicity assessments showed favorable results. Promising interactions with drug targets were observed in bioactivity tests.</p><p><strong>Conclusion: </strong>Fargesin from Chrysanthemum indicum may hold potential as a therapeutic agent for migraines.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2428119"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Panduratin A mitigates inflammation and oxidative stress in DSS-induced colitis mice model. Panduratin A能减轻DSS诱导的结肠炎小鼠模型的炎症和氧化应激反应。
IF 2.4 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 Epub Date: 2024-11-19 DOI: 10.1080/20565623.2024.2428129
Abdelrahim Alqudah, Esam Qnais, Omar Gammoh, Yousra Bseiso, Mohammed Wedyan, Muna Oqal

Aim: This study explored Panduratin A's protective effects against DSS-induced colitis in mice, focusing on reducing inflammation and oxidative stress in the colon.

Methods: Mice were treated with dextran sodium sulfate (DSS) and Panduratin A (3, 6, 18 mg/kg), and changes in body weight, colon length, Disease Activity Index (DAI), histopathology, inflammation markers including tumor necrosis factor- α (TNF-α), Interleukin-1 β (IL-1β), Myeloperoxidase (MPO), and oxidative stress, Malondialdehyde (MDA) were evaluated.

Results: Panduratin A significantly reversed DSS-induced symptoms, including body weight loss, colonic length shortening, and DAI increase, while reducing histopathological damage. It lowered inflammatory markers and oxidative stress, suppressed NF-κB activation, and enhanced Nrf2 and HO-1 expression.

Conclusion: Panduratin A shows promise as a colitis treatment, warranting further research for broader clinical application.

目的:本研究探讨了 Panduratin A 对右旋糖酐硫酸钠诱导的小鼠结肠炎的保护作用,重点是减少结肠中的炎症和氧化应激:用葡聚糖硫酸钠(DSS)和 Panduratin A(3、6、18 毫克/千克)治疗小鼠,评估小鼠体重、结肠长度、疾病活动指数(DAI)、组织病理学、肿瘤坏死因子-α(TNF-α)、白细胞介素-1 β(IL-1β)、髓过氧化物酶(MPO)等炎症标志物和丙二醛(MDA)等氧化应激的变化:结果:Panduratin A能明显逆转DSS诱导的症状,包括体重减轻、结肠长度缩短和DAI增加,同时减轻组织病理学损伤。它降低了炎症指标和氧化应激,抑制了NF-κB的激活,并增强了Nrf2和HO-1的表达:结论:Panduratin A有望作为结肠炎的治疗药物,值得进一步研究以扩大临床应用。
{"title":"Panduratin A mitigates inflammation and oxidative stress in DSS-induced colitis mice model.","authors":"Abdelrahim Alqudah, Esam Qnais, Omar Gammoh, Yousra Bseiso, Mohammed Wedyan, Muna Oqal","doi":"10.1080/20565623.2024.2428129","DOIUrl":"10.1080/20565623.2024.2428129","url":null,"abstract":"<p><strong>Aim: </strong>This study explored Panduratin A's protective effects against DSS-induced colitis in mice, focusing on reducing inflammation and oxidative stress in the colon.</p><p><strong>Methods: </strong>Mice were treated with dextran sodium sulfate (DSS) and Panduratin A (3, 6, 18 mg/kg), and changes in body weight, colon length, Disease Activity Index (DAI), histopathology, inflammation markers including tumor necrosis factor- α (TNF-α), Interleukin-1 β (IL-1β), Myeloperoxidase (MPO), and oxidative stress, Malondialdehyde (MDA) were evaluated.</p><p><strong>Results: </strong>Panduratin A significantly reversed DSS-induced symptoms, including body weight loss, colonic length shortening, and DAI increase, while reducing histopathological damage. It lowered inflammatory markers and oxidative stress, suppressed NF-κB activation, and enhanced Nrf2 and HO-1 expression.</p><p><strong>Conclusion: </strong>Panduratin A shows promise as a colitis treatment, warranting further research for broader clinical application.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2428129"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating outcomes of coronary artery bypass graft (CABG) surgery: a single-center retrospective study in Jordan. 冠状动脉旁路移植手术(CABG)疗效调查:约旦单中心回顾性研究。
IF 2.4 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-12-01 Epub Date: 2024-11-25 DOI: 10.1080/20565623.2024.2430902
Emad Hijazi

Background: Coronary artery bypass graft (CABG) surgery brings significant cardiac benefits but also risks post-operative complications, including cognitive impairments and infections.

Materials & methods: We analyzed 108 patient records between 2011 and 2021 at the Princess Muna Al-Hussein Cardiac Center, Irbid, Jordan. The primary endpoint was the occurrence of postoperative events.

Results: Few patients (8.3%) faced complications like stroke and infections, with age and ICU stay length as significant risk factors. Patients with complications often experienced left ventricular impairments and required inotropic support.

Conclusion: The study highlights the need for understanding CABG surgery complications to improve outcomes, emphasizing preventive care and personalized follow-up.

背景:冠状动脉旁路移植手术(CABG)为心脏带来了巨大的益处,但也存在术后并发症的风险,包括认知障碍和感染:我们分析了约旦伊尔比德穆纳侯赛因公主心脏中心 2011 年至 2021 年期间的 108 份患者记录。主要终点是术后事件的发生率:少数患者(8.3%)面临中风和感染等并发症,年龄和重症监护室住院时间是重要的风险因素。出现并发症的患者通常左心室功能受损,需要肌力支持:这项研究强调了了解心血管造影术并发症以改善预后的必要性,同时强调了预防性护理和个性化随访。
{"title":"Investigating outcomes of coronary artery bypass graft (CABG) surgery: a single-center retrospective study in Jordan.","authors":"Emad Hijazi","doi":"10.1080/20565623.2024.2430902","DOIUrl":"10.1080/20565623.2024.2430902","url":null,"abstract":"<p><strong>Background: </strong>Coronary artery bypass graft (CABG) surgery brings significant cardiac benefits but also risks post-operative complications, including cognitive impairments and infections.</p><p><strong>Materials & methods: </strong>We analyzed 108 patient records between 2011 and 2021 at the Princess Muna Al-Hussein Cardiac Center, Irbid, Jordan. The primary endpoint was the occurrence of postoperative events.</p><p><strong>Results: </strong>Few patients (8.3%) faced complications like stroke and infections, with age and ICU stay length as significant risk factors. Patients with complications often experienced left ventricular impairments and required inotropic support.</p><p><strong>Conclusion: </strong>The study highlights the need for understanding CABG surgery complications to improve outcomes, emphasizing preventive care and personalized follow-up.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2430902"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11591588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142709805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Promising approach for targeting ROBO1 with CAR NK cells to combat ovarian cancer primary tumor cells and organoids. 利用 CAR NK 细胞靶向 ROBO1 对抗卵巢癌原发肿瘤细胞和器官组织的方法前景广阔。
IF 2.4 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-07-11 Epub Date: 2024-07-29 DOI: 10.2144/fsoa-2023-0135
Yan Zhu, Luanhong Wang, Biyu Jiang, Yini Wang, Qing Wu, Sihua Hong, Xiaojing Wang, Yuancheng Li, Tian Guan, Haoyu Zeng, Congzhu Li

Aim: This study aimed to explore using peripheral blood mononuclear cell (PBMC)-derived chimeric antigen receptor (CAR) NK cells targeting ROBO1 as a personalized medicine approach for ovarian cancer. Methods: A two-step strategy generated ROBO1-targeted CAR NK cells from PBMCs of ovarian cancer patients. Efficacy was evaluated using xCELLigence RTCA, CCK-8 and Live/Dead fluorescence assays. Results: ROBO1-NK cells exhibited higher efficiency in eradicating primary ovarian cancer cells and lysing ovarian tumor organoids compared with primary NK cells without ROBO1-CAR modification. Conclusion: These findings highlight the potential of developing ROBO1-targeted CAR-NK cells from patients' PBMCs as a personalized treatment option for ovarian cancer.

目的:本研究旨在探索使用外周血单核细胞(PBMC)衍生的靶向 ROBO1 的嵌合抗原受体(CAR)NK 细胞作为卵巢癌的个体化治疗方法。方法:采用两步策略从卵巢癌患者的PBMC细胞中产生ROBO1靶向CAR NK细胞。使用 xCELLigence RTCA、CCK-8 和活/死荧光检测法评估疗效。结果显示与未经ROBO1-CAR修饰的原代NK细胞相比,ROBO1-NK细胞在消灭原代卵巢癌细胞和裂解卵巢肿瘤组织细胞方面表现出更高的效率。结论这些发现凸显了利用患者的 PBMCs 开发 ROBO1 靶向 CAR-NK 细胞作为卵巢癌个性化治疗方案的潜力。
{"title":"Promising approach for targeting ROBO1 with CAR NK cells to combat ovarian cancer primary tumor cells and organoids.","authors":"Yan Zhu, Luanhong Wang, Biyu Jiang, Yini Wang, Qing Wu, Sihua Hong, Xiaojing Wang, Yuancheng Li, Tian Guan, Haoyu Zeng, Congzhu Li","doi":"10.2144/fsoa-2023-0135","DOIUrl":"10.2144/fsoa-2023-0135","url":null,"abstract":"<p><p><b>Aim:</b> This study aimed to explore using peripheral blood mononuclear cell (PBMC)-derived chimeric antigen receptor (CAR) NK cells targeting ROBO1 as a personalized medicine approach for ovarian cancer. <b>Methods:</b> A two-step strategy generated ROBO1-targeted CAR NK cells from PBMCs of ovarian cancer patients. Efficacy was evaluated using xCELLigence RTCA, CCK-8 and Live/Dead fluorescence assays. <b>Results:</b> ROBO1-NK cells exhibited higher efficiency in eradicating primary ovarian cancer cells and lysing ovarian tumor organoids compared with primary NK cells without ROBO1-CAR modification. <b>Conclusion:</b> These findings highlight the potential of developing ROBO1-targeted CAR-NK cells from patients' PBMCs as a personalized treatment option for ovarian cancer.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2340186"},"PeriodicalIF":2.4,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11290772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of attitudes and practices toward gastroesophageal reflux disease among the general population of Pakistan. 分析巴基斯坦普通民众对胃食管反流病的态度和做法。
IF 2.5 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2024-06-06 eCollection Date: 2024-01-01 DOI: 10.2144/fsoa-2023-0144
Humaira Jabbar, Tooba Noor, Muhammad A Obaid, Areej Shakil, Muhammad I Obaid, Syeda I Aaqil, Usama Aa Memon, Zoha Mohsin

Aim: Gastro-esophageal reflux disease (GERD) is a growing health concern. Methods: In this cross-sectional study, participants' knowledge, attitude and practice toward GERD were assessed using a questionnaire. Results: In our study of 411 participants, 92.5% knew about GERD. Correctly identified risk factors were smoking (62.3%), fatty food (84.2%), spicy food (91.2%) and meal timing (80.8%). Identified symptoms were burning sensation (92.2%) and regurgitation (81.0%). 43.6% of participants were unaware of GERD's complications. Only 46.2% would seek medical advice for feeling full after eating, but 85% would for severe symptoms. 88.7 and 86.8% of participants showed willingness to amend diet and lifestyle. Conclusion: General population has knowledge regarding GERD and its risk factors but poor attitude and practices toward the condition.

目的:胃食管反流病(GERD)是一个日益严重的健康问题。研究方法在这项横断面研究中,通过问卷调查评估了参与者对胃食管反流病的认识、态度和做法。结果在我们对 411 名参与者进行的研究中,92.5% 的人知道胃食管反流病。正确识别的风险因素包括吸烟(62.3%)、油腻食物(84.2%)、辛辣食物(91.2%)和进餐时间(80.8%)。正确识别的症状是烧灼感(92.2%)和反胃(81.0%)。43.6%的参与者不知道胃食管反流病的并发症。只有 46.2% 的人在进食后感到饱胀时会寻求医疗建议,但 85% 的人在症状严重时会寻求医疗建议。88.7%和86.8%的参与者表示愿意改变饮食和生活方式。结论普通人群对胃食管反流病及其风险因素有所了解,但对该病的态度和做法却不佳。
{"title":"Analysis of attitudes and practices toward gastroesophageal reflux disease among the general population of Pakistan.","authors":"Humaira Jabbar, Tooba Noor, Muhammad A Obaid, Areej Shakil, Muhammad I Obaid, Syeda I Aaqil, Usama Aa Memon, Zoha Mohsin","doi":"10.2144/fsoa-2023-0144","DOIUrl":"10.2144/fsoa-2023-0144","url":null,"abstract":"<p><p><b>Aim:</b> Gastro-esophageal reflux disease (GERD) is a growing health concern. <b>Methods:</b> In this cross-sectional study, participants' knowledge, attitude and practice toward GERD were assessed using a questionnaire. <b>Results:</b> In our study of 411 participants, 92.5% knew about GERD. Correctly identified risk factors were smoking (62.3%), fatty food (84.2%), spicy food (91.2%) and meal timing (80.8%). Identified symptoms were burning sensation (92.2%) and regurgitation (81.0%). 43.6% of participants were unaware of GERD's complications. Only 46.2% would seek medical advice for feeling full after eating, but 85% would for severe symptoms. 88.7 and 86.8% of participants showed willingness to amend diet and lifestyle. <b>Conclusion:</b> General population has knowledge regarding GERD and its risk factors but poor attitude and practices toward the condition.</p>","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"10 1","pages":"2359843"},"PeriodicalIF":2.5,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141295907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Future Science OA
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1